Management of a New Isolated Metastasis during Sunitinib Treatment in Renal Cell Carcinoma Patients: A Lesson from Two Cases.
| dc.contributor.author | Shablak, Alaaeldin | |
| dc.contributor.author | O'Dwyer, Jackie F | |
| dc.contributor.author | Hawkins, Robert E | |
| dc.contributor.author | Board, Ruth E | |
| dc.date.accessioned | 2011-01-21T11:40:17Z | |
| dc.date.available | 2011-01-21T11:40:17Z | |
| dc.date.issued | 2010-12-02 | |
| dc.identifier.citation | Management of a New Isolated Metastasis during Sunitinib Treatment in Renal Cell Carcinoma Patients: A Lesson from Two Cases. 2010: Urol Int | en |
| dc.identifier.issn | 1423-0399 | |
| dc.identifier.pmid | 21124010 | |
| dc.identifier.doi | 10.1159/000321908 | |
| dc.identifier.uri | http://hdl.handle.net/10541/120152 | |
| dc.description.abstract | Metastatic renal cell carcinoma (mRCC) is a difficult to treat malignancy and currently Sunitinib is a standard of care first-line therapy. A new metastasis during the treatment is considered a sign of drug failure and alternative therapeutic methods should be tried. Here, we report 2 cases of newly diagnosed isolated metastasis during Sunitinib treatment of mRCC patients. Our management plan included local palliative therapy to the lesion followed by recommencing of Sunitinib. This resulted in a good symptomatic relief locally as well as good overall control of the disease. | |
| dc.language | ENG | |
| dc.language.iso | en | en |
| dc.subject | Renal Cell Carcinoma | en |
| dc.subject | Sunitinib Treatment | en |
| dc.subject | Palliative Therapy | en |
| dc.title | Management of a New Isolated Metastasis during Sunitinib Treatment in Renal Cell Carcinoma Patients: A Lesson from Two Cases. | en |
| dc.type | Article | en |
| dc.contributor.department | Department of Medical Oncology, Christie NHS Foundation Trust, Manchester, UK. | en |
| dc.identifier.journal | Urologia Internationalis | en |
| html.description.abstract | Metastatic renal cell carcinoma (mRCC) is a difficult to treat malignancy and currently Sunitinib is a standard of care first-line therapy. A new metastasis during the treatment is considered a sign of drug failure and alternative therapeutic methods should be tried. Here, we report 2 cases of newly diagnosed isolated metastasis during Sunitinib treatment of mRCC patients. Our management plan included local palliative therapy to the lesion followed by recommencing of Sunitinib. This resulted in a good symptomatic relief locally as well as good overall control of the disease. |